The future of CTCL therapy
4 意见
• 08/09/23
0
0
嵌入
Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论